Clinical Diagnosis

Retina experts unpack MacTel type 2—spot subtle signs, understand anti-VEGF limits, and explore emerging neuroprotective treatments.

Tenpoint Therapeutics’ YUVEZZI, expected in the US in Q2 2026, is the first fixed-dose combination drop designed to improve near vision via pupil modulation with once-daily dosing.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Oluwatosin U. Smith, MD, highlights the practical impact of expanding tools on real-world glaucoma treatment.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

The year introduced shifts in residency education, and program directors reflect on changes, challenges, and what’s next.

Sahar Bedrood, MD, PhD; Inder Paul Singh, MD; and AnnMarie Hipsley, DPT, PhD, recount moments that blended professional milestones with mentorship and legacy.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

Looking back on 2025, Neda Shamie shares how a challenging monocular patient reinforced the importance of patience, presence, and psychological support in ophthalmic care.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.

As artificial intelligence tools become more common in research, students must navigate issues including plagiarism, data consent, and equitable application.

Retina experts unpack MacTel type 2, why anti-VEGF falls short, and how new cell-based gene therapy fits real-world care.

Alternative management may avoid current concerns found with antibiotics.

A phase IV study in China found that 22 of 26 patients achieved complete healing of a persistent corneal epithelial defect or corneal ulcer after 8 weeks.

A study from a tertiary eye hospital suggests that effective keratitis management may have the potential to restore vision.

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of patient-centered eye care.

Second-year medical student Rishika Garg, from the University of Oklahoma College of Medicine in Oklahoma City, shares insights from a nationwide analysis revealing inconsistencies in ophthalmology residency leave policies.